Cytomedix To Host Fourth Quarter and Year
End 2009 Financial Results Conference Call On Tuesday, March
30, 2010
Rockville, MD, . (March 4,
2010) – Cytomedix, Inc. (AMEX:
GTF) a leading developer of biologically active
regenerative therapies for wound care, inflammation and
angiogenesis, today announced that the Company will release
financial results for the three and twelve months ended
December 31, 2009, following the close of the market on
Monday, March 29, 2010.
Martin Rosendale, Chief Executive Officer, and Andrew Maslan,
Chief Financial Officer, will host a conference call
beginning at 10:00 a.m. Eastern Time on Tuesday, March 30,
2010 to discuss the fourth quarter and year end 2009
financial results and to answer questions.
Shareholders and other interested parties may participate in
the conference call by dialing 800-884-5695 (domestic) or
617-786-2960 (international) and entering passcode 18617657
a few minutes before 10:00 a.m. ET on Tuesday, March 30,
2010. The call will also be broadcast live on the Internet
at
www.streetevents.com,
www.fulldisclosure.com and
www.cytomedix.com.
A replay of the conference call will be accessible two hours
after its completion through April 6, 2010 by dialing
888-286-8010 (domestic) or 617-801-6888 (international) and
entering passcode 64458581. The call will also be archived
for 90 days at
www.streetevents.com,
www.fulldisclosure.com and
www.cytomedix.com.
About Cytomedix
Cytomedix develops, sells
and licenses regenerative biological therapies including the
AutoloGel™ System, a device for the production of Platelet
Rich Plasma ("PRP") gel derived from the patient's own
blood. The AutoloGel™ System is cleared by the U.S. Food and
Drug Administration for use on a variety of exuding wounds.
The Company is pursuing a multi-faceted strategy to
penetrate the chronic wound market with its AutoloGel™
System. The Company is also moving forward with the
development of other product candidates in its pipeline.
Most notably is its CT-112 product, an anti-inflammatory
peptide that has shown promise in preclinical testing.
Additional information regarding Cytomedix is available at
www.cytomedix.com.
About Hair Transplant
Forum International
Hair Transplant Forum
International is a privately published newsletter of the
International Society of Hair Restoration Surgery. Its
contents are solely the opinions of the authors and are not
formally “peer reviewed” before publication. To facilitate
the free exchange of information, a less stringent standard
is employed to evaluate the scientific accuracy of the
letters and articles published in the Forum. The standard of
proof required for letters and articles is not to be
compared with that of formal medical journals. The
newsletter was designed to be and continues to be a printed
forum where specialists and beginners in hair restoration
techniques can exchange thoughts, experiences, opinions, and
pilot studies on all matters relating to hair restoration.
Safe Harbor Statement
Statements contained in
this communication not relating to historical facts are
forward-looking statements that are intended to fall within
the safe harbor rule for such statements under the Private
Securities Litigation Reform Act of 1995. The information
contained in the forward-looking statements is inherently
uncertain, and Cytomedix’s actual results may differ
materially due to a number of factors, many of which are
beyond Cytomedix’s ability to predict or control, including
among others, viability and effectiveness of the Company’s
sales approach and overall marketing strategies, the outcome
of development or regulatory review of CT-112, commercial
success or acceptance by the medical community, competitive
responses, the Company's ability to raise additional capital
and to continue as a going concern, its ability to
successfully commercialize its product in Japan under the
terms of the license agreement, and Cytomedix's ability to
execute on its strategy to market the AutoloGel™ System as
contemplated. These forward-looking statements are subject
to known and unknown risks and uncertainties that could
cause actual events to differ from the forward-looking
statements. More information about some of these risks and
uncertainties may be found in the reports filed with the
Securities and Exchange Commission by Cytomedix, Inc.
Cytomedix operates in a highly competitive and rapidly
changing business and regulatory environment, thus new or
unforeseen risks may arise. Accordingly, investors should
not place any reliance on forward-looking statements as a
prediction of actual results. Except as is expressly
required by the federal securities laws, Cytomedix
undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new
information, changed circumstances or future events or for
any other reason.
|
